McKennon SA, Campbell RKThe physiology of incretin hormones and the basis for DPP-4 inhibitors. Diabetes Educ. 2007;33:55-67.
4.
Amori RE, Lau J., Pittas AGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194-206.
5.
Druker DJ, Nauck MAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
6.
Kruger DF, Martin CL, Sadler CENew insights into glucose regulation. Diabetes Educ. 2006;32:221-228.
7.
McIntosh CHIncretin-based therapies for type 2 diabetes. Can J Diabetes . 2008;32:131-139.
8.
White JR Jr.Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabetes. 2008 ;26:53-57.
9.
Hood R., Valentine V., Mac S., Polonsky WHUse of exenatide in patients with type 2 diabetes. Diabetes Spectrum. 2006;19:181-186.
10.
Childs BP, Kesty NC, Klein E., et al. Considering pramlintide therapy for postprandial blood glucose control. Diabetes Spectrum. 2007;20:108-114.
11.
Heine RJ, Van Gaal LF, Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.
12.
Nauk MA, Hompesch M., Filipczak R., et al, for the NN221-1499 Study Group.Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114:417-423.
13.
Vilsboll T. , Brock B., Perrild H., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus . Diabet Med. 2008;25: 152-156.
14.
Blonde L., Rosenstock J., Sesti G., et al. Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes. Presented at: Canadian Diabetes Association Congress; October 15-18, 2008; Montreal, Quebec. Abstract 107.
15.
Pratley RE, Rosenstock J., Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care . 2007;30: 3017-3022.
16.
Ahrén B., Gomis R., Standl E., et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27: 2874-2880.
17.
Schweizer A. , Couturier A., Foley JE, Dejager S.Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med. 2007;24:955-961.
18.
Rosenstock J. , Baron MA, Dejager S., et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial [published correction appears in Diabetes Care. 2007;30:1330]. Diabetes Care. 2007;30:217-223.
19.
RichterB.,Bandeira-EchtlerE.,BergerhoffK.,LerchCLDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev.2008;16:CD006739.
